Company Analysis
Sign in

Inhibrx Biosciences, Inc. (INBX)

Nasdaq: INBX · Biological Products, (No Diagnostic Substances) · La Jolla, CA · filing with the SEC since 2024
Full chart Alerts Compare
Grade4.5
◀ Past 5.2● Present 4.2▶ Future 4.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

11 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Inhibrx Biosciences, Inc.’s names, not what it holds today.

Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
9
Against 2 in 2024 and none in 2023
Applications published
22
19 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology9
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Inhibrx Biosciences, Inc. its own name
US, as the owner printed on each patent
11 granted
17 published
Inhibrx Biosciences, Inc. its own name
named as the applicant on its applications, in US
0 granted
5 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 23, 202512,421,315CLL-1 targeted immunotherapiesBiotechnologyInhibrx Biosciences, Inc.
Jul 22, 202512,365,728DLL3 single domain antibodies and therapeutic compositions thereofBiotechnologyInhibrx Biosciences, Inc.
Jun 17, 202512,331,132Multispecific polypeptide constructs having constrained CD3 binding and related methods and usesBiotechnologyInhibrx Biosciences, Inc.
Jun 17, 202512,331,126OX40-binding polypeptides and uses thereofBiotechnologyInhibrx Biosciences, Inc.
May 13, 202512,297,271PD-1 single domain antibodies and therapeutic compositions thereofBiotechnologyInhibrx Biosciences, Inc.
Feb 25, 202512,234,297IgE binding proteins and uses thereofBiotechnologyInhibrx Biosciences, Inc.
Feb 18, 202512,227,584Multivalent and multispecific OX40-binding fusion proteinsPharmaceuticalsInhibrx Biosciences, Inc.
Jan 14, 202512,195,533Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the sameBiotechnologyInhibrx Biosciences, Inc.
Jan 7, 202512,187,804Multivalent and multispecific 41BB-binding proteinsPharmaceuticalsInhibrx Biosciences, Inc.
Sep 10, 202412,084,502CD33-binding polypeptides and uses thereofBiotechnologyInhibrx Biosciences, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0361319MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USESBiotechnologyInhibrx Biosciences, Inc.
Nov 20, 20252025/0353911FcRn-Binding Polypeptides and Uses ThereofPharmaceuticalsInhibrx Biosciences, Inc.
Oct 30, 20252025/0332098Formulations of DR5 Binding PolypeptidesPharmaceuticalsInhibrx Biosciences, Inc.
Oct 16, 20252025/0320295CD8-Binding Polypeptides and Uses ThereofBiotechnologyInhibrx Biosciences, Inc.
Oct 9, 20252025/0313623DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOFBiotechnologyInhibrx Biosciences, Inc.
Oct 2, 20252025/0302948DR5 Agonist and IAP Antagonist Combination TherapyPharmaceuticalsInhibrx Biosciences, Inc.
Sep 4, 20252025/0277018Albumin-Binding Polypeptides and Uses ThereofBiotechnologyInhibrx Biosciences, Inc.
Aug 7, 20252025/0250349USES OF PDL1-BINDING PROTEINSPharmaceuticalsInhibrx Biosciences, Inc.
Jul 10, 20252025/0223338NON-IMMUNOGENIC SINGLE DOMAIN ANTIBODIESBiotechnologyInhibrx Biosciences, Inc.
Jul 3, 20252025/0215101DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination TherapyPharmaceuticalsInhibrx Biosciences, Inc.
What it applied for, 2024 to 2025: Biotechnology 14 · Pharmaceuticals 8.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton INBX · research, not advice